Verstovsek, Srdan
Funding for this research was provided by:
Incyte
Article History
Received: 7 December 2022
Accepted: 2 February 2023
First Online: 14 February 2023
Declarations
:
: SV received research support from AstraZeneca, Blueprints Medicines Corp., Celgene, CTI BioPharma Corp., Genentech, Gilead, Incyte, ItalPharma, Novartis, NS Pharma, PharmaEssentia, Promedior, Protagonist Therapeutics, Roche, and Sierra Oncology; and is a paid consultant for Celgene, Incyte, Novartis, and Sierra Oncology.